Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J. Harding, Sebastián Mondaca, Jin Won Kim et al.|The Lancet Oncology|2023Cited by 243
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal CancerThierry André, Sara Lonardi, Elena Élez et al.|New England Journal of Medicine|2024Cited by 208